Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
PHARMA - HIV DRUGS

GlaxoSmithKline begins phase III trials of new HIV drug

 

BY OUR PHARMA CORRESPONDENT

13th August,2005:GlaxoSmithKline (GSK) announced that phase III clinical studies with its entry inhibitor aplaviroc (873140) have commenced in HIV treatment-experienced patients.

Entry inhibitors like aplaviroc represent a new mechanism of action in this class of antiretrovirals. They work by binding to one of the chemokine co-receptors, CCR5, on the immune cell surface that is essential for HIV-1 entry and infection.

The availability of an orally administered entry inhibitor may provide an important treatment option for people infected with HIV-1, the company said in an official release.

Aplaviroc selectively inhibits the binding of the HIV envelope to the CCR5 co-receptor on the cell surface by producing changes in the receptor conformation via an allosteric mechanism. Allosteric inhibition occurs when an interaction in one region of a protein prevents the function of another part of the protein. This affects the interaction of the virus with the cell, as HIV cannot use the antagonist-bound CCR5 pathway. The viral entry cascade and subsequent infection by CCR5-using HIV are therefore blocked.

GSK also hosted a satellite symposium at the 3rd International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment in Rio de Janeiro, Brazil, highlighting the company’s progress in the development of new treatments for HIV. Antiretroviral drug resistance is a major cause of treatment failure in patients infected with HIV-1 and has been associated with increased mortality. To address the continued need for new anti-HIV drugs, GSK has a number of drugs in development that hope to demonstrate activity against viral strains that are resistant to existing agents. In addition to aplaviroc, investigational compound 640385 is in phase II development as a next-generation protease inhibitor (PI); and 695634 is in phase II development as a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI). Both compounds are being evaluated for treatment of those patients whose virus has become resistant to multiple antiretroviral drugs.

Aplaviroc is the proposed generic name for 873140. It was in-licensed for development from Ono Pharmaceutical Co., Ltd. in December 2002. 640385 was co-discovered with Vertex Pharmaceuticals, Inc, the GSK release added.
GlaxoSmithKline is one of the world's leading pharmaceutical and healthcare companies The company is a leader in HIV/AIDS treatments to patients and provides its anti-retrovirals to 64 of the least developed countries and Sub-Saharan Africa at not-for-profit prices.

BY OUR PHARMA CORRESPONDENT

Pharma News Headlines

Cancer News

Cardiac News

US FDA News

Pharma industry news

LATEST UPDATES

Heart disease deaths more among New Yorkers

Pfizer to offer drugs risk/benefit summary to consumers 

Merck lied to public on Vioxx: lawyer tells jurors

Novartis acquires rights of kidney dialysis drug from SeBo

J&J's Concerta approved treatment of ADHD in teenagers in Canada

US FDA stalls Roche’ Accutane use in pregnancy

Novo Nordisk, Eli Lilly remove insulin products from Australia

British drug supply chain safety questioned after another fake Lipitor find

Wyeth starts support programme for Effexor patients

P&G’s Actonel with Calcium approved for osteoporosis

Pozen gets patent on pain management product

Genmab studies new drug for rheumatoid arthritis

Painkillers may increase blood pressure: study

Nektar buys out Aerogen for $32 m

Predix records positive data on anxiety drug

Insmed files against Increlex approval

Hepatitis A vaccine for kids approved in US

Psoriasis drug data positive: Cytochroma

Novo Nordisk’s 24-hour acting insulin Levemir gets US FDA okay

US FDA approves Teva's generic for osteoporosis 

Pfizer files NDA for Sutent in US

BioVeris licenses Baxter's vaccine portfolio

TheraQuest receives 2nd Orphan Drug status for neuralgia drug

Real-time glucose monitoring device approved in US

Halozyme gets FDA nod for bladder cancer therapy

Migenix to commence phase 2b studies in hep C therapy

Barr gets US FDA okay for clonazepam tabs

Anorexia drug study results positive: Par

GlaxoSmithKline begins phase III trials of new HIV drug

Ranbaxy's 7 anti retrovirals included in WHO list

FDA tightens restrictions on acne drug

Voglibose tabs launched in Japan

Remicade researcher gifts $ 105m to NYU

Par loses ondansetron case to GSK

Mistral starts clinical studies for generic

Carl Icahn sells Mylan shares

Florida sues Mylan, Teva and Watson

Dey and Connecticut settle pricing dispute

Germany set to stop rabies crossing borders

Office to review DTC drug advertisements in US

British docs to be trained in communication, safety

FDA okays acrylic lens for cataract patients 

Corautus to go ahead with angina drug studies 

Americans turn the low-fat way

Chemicals in plastics pose danger

US committee probes doctors’ complicity with Wall Street analysts

Meda buys out rival Viatris

US FDA nod for new levofloxacin regimen to treat acute bacterial sinusitis

Pozen files for new migraine treatment

New therapy for pancreatic cancer under review

New device inducing blood flow to heart granted US patent

NIH announces grants for faster, cheaper DNA sequencing

DOV starts phase III trial of pain drug in US

Alcohol linked cancers: Acetaldehyde in spot light

Hypertension `just above normal’ too risky

Gene causes infertility drugs go awry: study

China’s pig flu outbreak

Cardiac Science-Defibtech lawsuit settled

Peregrine starts Phase-1 anti-viral trial of Tarvacin

Dr. Reddy's launches immune booster for children

Lupin in pact with Kyowa of Japan

Bird flu vaccine may work in humans: US researchers

 

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us